Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $353.5 million.

  • Amphastar Pharmaceuticals' Non-Current Assets rose 794.06% to $353.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.5 million, marking a year-over-year increase of 794.06%. This contributed to the annual value of $344.6 million for FY2024, which is 918.25% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Non-Current Assets stood at $353.5 million, which was up 794.06% from $354.7 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Non-Current Assets ranged from a high of $899.3 million in Q3 2023 and a low of $259.8 million during Q3 2022
  • Over the past 5 years, Amphastar Pharmaceuticals' median Non-Current Assets value was $315.6 million (recorded in 2023), while the average stood at $423.8 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Non-Current Assets soared by 24615.01% in 2023 and then tumbled by 6358.04% in 2024.
  • Amphastar Pharmaceuticals' Non-Current Assets (Quarter) stood at $271.5 million in 2021, then dropped by 2.55% to $264.6 million in 2022, then rose by 19.3% to $315.6 million in 2023, then rose by 9.18% to $344.6 million in 2024, then rose by 2.58% to $353.5 million in 2025.
  • Its last three reported values are $353.5 million in Q3 2025, $354.7 million for Q2 2025, and $353.8 million during Q1 2025.